Kuros Biosciences (VTX:KURN) rallies 9.4% this week, taking one-year gains to 805%

While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great companies, and generate wonderful returns. When an investor finds a multi-bagger (a stock that goes up over 200%), it makes a big difference to their portfolio. For example, the Kuros Biosciences AG (VTX:KURN) share price is up a whopping 805% in the last 1 year, a handsome return in a single year. Also pleasing for shareholders was the 79% gain in the last three months. Looking back further, the stock price is 715% higher than it was three years ago. Anyone who held for that rewarding ride would probably be keen to talk about it.

Since it's been a strong week for Kuros Biosciences shareholders, let's have a look at trend of the longer term fundamentals.

See our latest analysis for Kuros Biosciences

Because Kuros Biosciences made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Kuros Biosciences grew its revenue by 157% last year. That's stonking growth even when compared to other loss-making stocks. But the share price seems headed to the moon, up 805% as previously highlighted. Even the most bullish shareholders might be thinking that the share price might drop back a bit, after a gain like that. But if the share price does moderate a bit, there might be an opportunity for high growth investors.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

If you are thinking of buying or selling Kuros Biosciences stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

It's good to see that Kuros Biosciences has rewarded shareholders with a total shareholder return of 805% in the last twelve months. Since the one-year TSR is better than the five-year TSR (the latter coming in at 58% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for Kuros Biosciences you should be aware of, and 2 of them can't be ignored.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Swiss exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.